Most IV sessions run $170 to $280. California's pharmacy board has called these clinics largely unregulated, and experts question the benefits.
Recap by typeshit. Full story at Berkeleyside.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
The Wall Street Journal traces how suppliers tied to fentanyl precursors have moved into selling gray-market peptides to American buyers.
Lab scientists explain how they tell deamidation and racemization byproducts apart from the main drug, using high-resolution MS and 2D-LC.
Loading…